Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4939-4941

  Layeux, Brice ^a   Taccone, Fabio Silvio ^a   Fagnoul, David ^a   Vincent, Jean Louis ^a   Jacobs, Frédérique ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; BETA LACTAM; CEFEPIME; CIPROFLOXACIN; COLISTIN; CREATININE; FLUCONAZOLE; FOSFOMYCIN; GENTAMICIN; MEROPENEM; TOBRAMYCIN;

ABDOMINAL ABSCESS; ABSCESS DRAINAGE; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; BODY MASS; CANDIDA ALBICANS; CASE REPORT; CHRONIC KIDNEY FAILURE; CONTINUOUS HEMODIAFILTRATION; CREATININE BLOOD LEVEL; DETERIORATION; DNA SEQUENCE; DRUG DOSE INCREASE; ELECTIVE SURGERY; EMPYEMA; ENDOPROSTHESIS; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPSIS; SEPTIC SHOCK; SLEEVE GASTRECTOMY; STOMACH FISTULA; STOMACH PERFORATION; THORAX EMPYEMA; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; SEPSIS;

EID: 78049309882     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00441-10     Document Type: Article

References (14)

1. Bressolle, F., J. M. Kinowski, J. E. de la Coussaye, N. Wynn, J. J. Eledjam, and M. Galtier. 1994. Clinical pharmacokinetics during continuous haemofiltration. Clin. Pharmacokinet. 26:457-471.
2. Drusano, G. L., P. G. Ambrose, S. M. Bhavnani, J. S. Bertino, A. N. Nafziger, and A. Louie. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760.
3. EUCAST. 15 June 2009. Aminoglycosides: EUCAST clinical MIC breakpoints. European Committee on Antibiotic Susceptibility Testing (EUCAST). http://www.srga.org/eucastwt/mictab/MICaminoglycosides.html. Accessed July 2010.
4. Falagas, M. E., and I. A. Bliziotis. 2007. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 29:630-636.
5. Lister, P. D., D. J. Wolter, and N. D. Hanson. 2009. Antibacterial- resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610.
6. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
7. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-1364.
8. Page, M. G., and J. Heim. 2009. Prospects for the next anti-Pseudomonas drug. Curr. Opin. Pharmacol. 9:558-565.
9. Rea, R. S., B. Capitano, R. Bies, K. L. Bigos, R. Smith, and H. Lee. 2008. Suboptimal aminoglycoside dosing in critically ill patients. Ther. Drug Monit. 30:674-681.
10. Rybak, M. J., B. J. Abate, S. L. Kang, M. L. Ruffing, S. A. Lerner, and G. L. Drusano. 1999. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1549-1555.
11. Safdar, N., J. Handelsman, and D. G. Maki. 2004. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A metaanalysis. Lancet Infect. Dis. 4:519-527.
12. Shorr, A. F. 2009. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit. Care Med. 37:1463-1469.
13. Taccone, F. S., P. F. Laterre, H. Spapen, T. Dugernier, I. Delattre, B. Layeux, D. De Backer, X. Wittebole, P. Wallemacq, J. L. Vincent, and F. Jacobs. 2010. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit. Care 14:R53.
14. Trotman, R. L., J. C. Williamson, D. M. Shoemaker, and W. L. Salzer. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41:1159-1166.